Oral Biologics & Biosimilar Drugs Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Oral Biologics & Biosimilar Drugs Market Growth Potential: How Will Market Size Change Through 2030?
The market for oral biologics and biosimilar drugs has experienced remarkable expansion in recent years, with projections showing an increase from $8.6 billion in 2025 to $10.41 billion in 2026, reflecting a compound annual growth rate (CAGR) of 21.0%. This historical growth has been driven by factors such as the scarce availability of oral biologics, a heavy dependence on injectable biologics, a growing incidence of autoimmune and inflammatory conditions, heightened patient demand for affordable treatment options, and the early regulatory approvals granted to monoclonal antibody drugs.
The oral biologics and biosimilar drugs market is poised for significant expansion in the coming years. Projections indicate it will reach $17.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.3%. This forward momentum is driven by several key factors: the creation of next-generation oral biologics, an expanding biosimilar pipeline, a growing preference for combination therapies, the increasing role of digital health platforms in patient monitoring, and heightened regulatory support for biosimilar approvals. Furthermore, notable trends shaping this period include the rising uptake of oral biologics and biosimilars, a strengthened focus on managing chronic diseases with biologics, broader distribution networks through hospital and retail pharmacies, improved patient understanding and acceptance of biosimilars, and the advancement of targeted treatments for autoimmune and inflammatory conditions.
Download A Free Sample Report For Comprehensive Market Insights:
Oral Biologics & Biosimilar Drugs Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing frequency of chronic conditions like arthritis, asthma, and cancer is anticipated to significantly influence the oral biologics and biosimilar market. Factors such as extended work schedules, sedentary lifestyles, and poor dietary and drinking habits contribute to the onset of these diseases, and biologics are being employed more frequently in their management. These therapies function by stimulating immune responses to target cancer cells, supporting the body’s ability to eliminate them. For example, as reported in a United Nations article from May 2023, chronic diseases are forecast to account for 70% of all global deaths by 2030, with the worldwide burden of such illnesses expected to approach approximately 60%. Consequently, this growing prevalence of chronic diseases is expected to boost demand for biologics and biosimilars, thereby fueling the expansion of the oral biologics and biosimilar drugs market.
Oral Biologics & Biosimilar Drugs Market Segments: Where Are The Largest Growth Opportunities?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Oral Biologics & Biosimilar Drugs Market Trends Reshaping Industry Growth
Key industry players in the oral biologics and biosimilar markets are concentrating on innovative products like incretin triagonists, aiming to enhance patient outcomes, boost drug effectiveness, and deliver substitutes for injectable therapies. These triagonists are medications that activate three hormone receptors simultaneously—GLP-1, GIP, and glucagon—which assist in controlling blood sugar, appetite, and metabolic processes. For example, in October 2024, Rani Therapeutics Holdings Inc., a biotechnology firm based in the US, unveiled fresh preclinical pharmacokinetic data supporting the transenteric administration of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule crafted for delivering biologics that traditionally necessitate injections, effectively administered a triagonist targeting GLP-1, GIP, and glucagon receptors—crucial targets in obesity management. The RaniPill showed comparable effectiveness to subcutaneous injections, providing a needle-free option with high bioavailability and flexible dosing, positioning it as a viable candidate for obesity medications.
Oral Biologics & Biosimilar Drugs Market Major Participants And Competitive Dynamics
Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
Access The Complete Oral Biologics & Biosimilar Drugs Market Report:
Oral Biologics & Biosimilar Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
